Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI3003 plus anti-CD38 antibody in multiple myeloma (Phase II, multicenter, open-label)
CTR20263125Phase 2Active
- Sponsor
- InnoCare Pharma
- Start
- Aug 2026
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of IBI3003 in multiple myeloma (MM), sponsored by InnoCare Pharma. Started Aug 2026; status: active.
02
Drugs
IBI3003
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on CTR20263125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263125.